BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24658158)

  • 1. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
    Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
    Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
    Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
    Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
    Lubensky IA; Schmidt L; Zhuang Z; Weirich G; Pack S; Zambrano N; Walther MM; Choyke P; Linehan WM; Zbar B
    Am J Pathol; 1999 Aug; 155(2):517-26. PubMed ID: 10433944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
    Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
    Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
    Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene.
    Glukhova L; Lavialle C; Fauvet D; Chudoba I; Danglot G; Angevin E; Bernheim A; Goguel AF
    Oncogene; 2000 Feb; 19(6):754-61. PubMed ID: 10698493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
    Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
    Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
    Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
    Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
    Durinck S; Stawiski EW; Pavía-Jiménez A; Modrusan Z; Kapur P; Jaiswal BS; Zhang N; Toffessi-Tcheuyap V; Nguyen TT; Pahuja KB; Chen YJ; Saleem S; Chaudhuri S; Heldens S; Jackson M; Peña-Llopis S; Guillory J; Toy K; Ha C; Harris CJ; Holloman E; Hill HM; Stinson J; Rivers CS; Janakiraman V; Wang W; Kinch LN; Grishin NV; Haverty PM; Chow B; Gehring JS; Reeder J; Pau G; Wu TD; Margulis V; Lotan Y; Sagalowsky A; Pedrosa I; de Sauvage FJ; Brugarolas J; Seshagiri S
    Nat Genet; 2015 Jan; 47(1):13-21. PubMed ID: 25401301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular classification of papillary renal cell carcinoma.
    Yang XJ; Tan MH; Kim HL; Ditlev JA; Betten MW; Png CE; Kort EJ; Futami K; Furge KA; Takahashi M; Kanayama HO; Tan PH; Teh BS; Luan C; Wang K; Pins M; Tretiakova M; Anema J; Kahnoski R; Nicol T; Stadler W; Vogelzang NG; Amato R; Seligson D; Figlin R; Belldegrun A; Rogers CG; Teh BT
    Cancer Res; 2005 Jul; 65(13):5628-37. PubMed ID: 15994935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
    Courthod G; Tucci M; Di Maio M; Scagliotti GV
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
    Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
    Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
    Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
    Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
    Zhuang Z; Park WS; Pack S; Schmidt L; Vortmeyer AO; Pak E; Pham T; Weil RJ; Candidus S; Lubensky IA; Linehan WM; Zbar B; Weirich G
    Nat Genet; 1998 Sep; 20(1):66-9. PubMed ID: 9731534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma.
    Prat E; Bernués M; Del Rey J; Camps J; Ponsa I; Algaba F; Egozcue J; Caballín MR; Gelabert A; Miró R
    Cancer Genet Cytogenet; 2006 Jan; 164(2):142-7. PubMed ID: 16434318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET as a target in papillary renal cell carcinoma.
    Fay AP; Signoretti S; Choueiri TK
    Clin Cancer Res; 2014 Jul; 20(13):3361-3. PubMed ID: 24812413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.